StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Zavicefta (ceftazidime/avibactam by Quarter

Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Zavicefta (ceftazidime/avibactam: $199M in Q2 2026, up 22.1% from a year earlier. That is the highest of the 27 quarters on record here.

Latest, Q2 2026
199
Period ended Jun 28, 2026
Change on a year earlier
+22.1%
163 in Q2 2025
History
27 quarters
Since Q4 2019
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Zavicefta (Outside the U.S. and Canada) | 199 | 163 | 22% | 17% | — | — | — | 199 | 163 | 22% | 17%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — International revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026199+22.1%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026150+11.1%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025181+13.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025158+3.9%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025163+8.7%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025135+8.0%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024159+19.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024152+16.9%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024150+13.6%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024125+7.8%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023133+22.0%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023130+32.7%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 2023132+32.0%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023116+11.5%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 2022109+1.9%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 202298-8.4%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗

Breakdown

What makes up zavicefta (ceftazidime/avibactam

Cite this data

StockData. (2026). Pfizer Zavicefta (ceftazidime/avibactam ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zavicefta-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?